VOR
Vor Biopharma Inc.
$14.36
+1.92%
$778.1M
No data for this timeframe.
Vol
Market Cap$778.1M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders30 funds
Inst. Value$234.3M
Inst. Activity7 buys / 1 sells
Insider Activity0B / 11S
Insider Net $-$46.3M
SEC Reports4
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001817229·Prev Close $14.09
Recent Activity
Jun 11, 2026
SEC
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) collectively mor
INST-CLUSTER — Impact 3/10
Jun 11, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. was granted 57,162 shares
Director
Jun 11, 2026
Insider
Detheux Michel was granted 57,162 shares
Director
Jun 11, 2026
Insider
Namouni Fouad was granted 56,549 shares
Director
Jun 8, 2026
Press
Vor Biopharma announced that China's NMPA conditionally approved telitacicept for IgA nephropathy, the first BAFF/APRIL-
Impact 7/10
Jun 8, 2026
other
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
<p align="center"><em>First regulatory approval for Sjögren’s disease (SjD)</em></p>
May 7, 2026
SEC
Vor Biopharma's S-3 registration statement (File No. 333-295346) became effective on May 6, 2026, enabling the resale of
EFFECT — Impact 3/10
Apr 27, 2026
SEC
Vor Biopharma filed an S-3 registration statement to register 5,338,078 shares of common stock for resale by TCG Crossov
S-3 — Impact 3/10
Price Targets
$37.88
+163.8% upside
Strong Buy
Current $14.36
Low $18.00
Median $40.00
High $50.00
8 analysts
$18.00
$50.00
Analyst Ratings
5Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 14, 2026 | Wedbush | MAINTAIN | Neutral → Neutral |
| Apr 15, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 31, 2026 | Wedbush | MAINTAIN | Neutral → Neutral |
| Mar 30, 2026 | Jefferies | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.70 ▲ +12.6% | $-0.82 — $-0.59 | 100% YoY | 2 |
| Next Q | $-0.77 ▲ +10.1% | $-0.95 — $-0.59 | 99% YoY | 2 |
| Current FY | $-6.90 ▼ -103.7% | $-8.00 — $-5.80 | 90% YoY | 2 |
| Next FY | $-3.74 ▼ -1.0% | $-4.50 — $-2.58 | 46% YoY | 5 |
Latest Reports
NEUTRAL
INST-CLUSTER
3/10
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) collectively mor
Jun 11, 2026
BULLISH
Press
7/10
Vor Biopharma announced that China's NMPA conditionally approved telitacicept for IgA nephropathy, the first BAFF/APRIL-
Jun 8, 2026
NEUTRAL
EFFECT
3/10
Vor Biopharma's S-3 registration statement (File No. 333-295346) became effective on May 6, 2026, enabling the resale of
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $96.4M | DOUBLED |
| FMR LLC | $27.5M | TRIM |
| VANGUARD CAPITAL MANAGEMENT LLC | $25.6M | — |
| MARSHALL WACE, LLP | $20.6M | NEW |
| STATE STREET CORP | $20.0M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 11, 2026 | RA CAPITAL | A | $0.00 |
| Jun 11, 2026 | Detheux Michel | A | $0.00 |
| Jun 11, 2026 | Namouni Fouad | A | $0.00 |
| Jun 11, 2026 | Joustra Wouter | A | $0.00 |
| Jun 11, 2026 | Cumbo Alexander | A | $0.00 |
30 institutional holders with $234.3M total value (13,134,343 shares) as of 2026-Q1. Top holders: RA, FMR, VANGUARD. Net buying activity: 7 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 5,404,998 | $96.4M | 41.2% | DOUBLED +172.7% |
| 2 | FMR LLC | 1,539,670 | $27.5M | 11.7% | TRIM -39.1% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1,433,280 | $25.6M | 10.9% | — |
| 4 | MARSHALL WACE, LLP | 1,153,276 | $20.6M | 8.8% | NEW |
| 5 | STATE STREET CORP | 1,118,458 | $20.0M | 8.5% | DOUBLED +1128.4% |
| 6 | BlackRock, Inc. | 794,759 | $14.2M | 6.1% | ADD +70.7% |
| 7 | GOLDMAN SACHS GROUP INC | 261,891 | $4.7M | 2.0% | — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 232,608 | $4.1M | 1.8% | — |
| 9 | VANGUARD FIDUCIARY TRUST CO | 185,511 | $3.3M | 1.4% | — |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 176,200 | $3.1M | 1.3% | — |
| 11 | TUDOR INVESTMENT CORP ET AL | 152,571 | $2.7M | 1.2% | — |
| 12 | CITADEL ADVISORS LLC | 148,768 | $2.7M | 1.1% | — |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 128,839 | $2.3M | 1.0% | — |
| 14 | MORGAN STANLEY | 116,721 | $2.1M | 0.9% | DOUBLED +310.1% |
| 15 | BANK OF AMERICA CORP /DE/ | 112,892 | $2.0M | 0.9% | DOUBLED +28408.1% |
| 16 | Rafferty Asset Management, LLC | 50,505 | $901.0K | 0.4% | — |
| 17 | Brevan Howard Capital Management LP | 42,217 | $753.2K | 0.3% | — |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 22,216 | $396.3K | 0.2% | — |
| 19 | SEI INVESTMENTS CO | 13,716 | $244.5K | 0.1% | — |
| 20 | Vanguard Global Advisers, LLC | 12,875 | $229.7K | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | TRIM | 2,526,170 | 1,539,670 | -39.1% | $27.5M | 2026-Q1 |
| MARSHALL WACE, LLP | NEW | — | 1,153,276 | — | $20.6M | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 91,053 | 1,118,458 | +1128.4% | $20.0M | 2026-Q1 |
| BlackRock, Inc. | ADD | 465,636 | 794,759 | +70.7% | $14.2M | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 28,463 | 116,721 | +310.1% | $2.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 396 | 112,892 | +28408.1% | $2.0M | 2026-Q1 |
| Mirae Asset Global Investments Co., Ltd. | DOUBLED | 819 | 2,166 | +164.5% | $38.6K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 3 | 73 | +2333.3% | $1.3K | 2026-Q1 |
| RA CAPITAL MANAGEMENT, L.P. | DOUBLED | 1,982,301 | 5,404,998 | +172.7% | $70.7M | 2025-Q4 |
| FMR LLC | DOUBLED | 236,508 | 2,526,170 | +968.1% | $33.0M | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 105,190 | 770,250 | +632.2% | $10.1M | 2025-Q4 |
| BlackRock, Inc. | DOUBLED | 34,530 | 465,636 | +1248.5% | $6.1M | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 9,054 | 91,053 | +905.7% | $1.2M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 4,456 | 28,463 | +538.8% | $372.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 4,754 | 396 | -91.7% | $5.2K | 2025-Q4 |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 1,982,301 | — | $96.6M | 2025-Q3 |
| FMR LLC | NEW | — | 236,508 | — | $11.5M | 2025-Q3 |
8 unique insiders with 19 transactions. Net insider value: -$46.3M ($0.00 bought, $46.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 57,162 | — | — |
| Jun 11, 2026 | Detheux Michel | Director | AWARD | 57,162 | — | — |
| Jun 11, 2026 | Namouni Fouad | Director | AWARD | 56,549 | — | — |
| Jun 11, 2026 | Joustra Wouter | Director | AWARD | 57,162 | — | — |
| Jun 11, 2026 | Cumbo Alexander | Director | AWARD | 56,345 | — | — |
| Jun 11, 2026 | Beckman Daniella | Director | AWARD | 53,283 | — | — |
| Jun 11, 2026 | Kalir Erez | Director | AWARD | 57,162 | — | — |
| Jun 11, 2026 | Levin Andrew David | Director | AWARD | 57,162 | — | — |
| Apr 22, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 165,150 | $15.77 | $2.6M |
| Apr 20, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 171,963 | $15.77 | $2.7M |
| Apr 17, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 458,411 | $16.28 | $7.5M |
| Apr 15, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 53,644 | $16.01 | $858.8K |
| Apr 14, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 153,735 | $15.97 | $2.5M |
| Apr 13, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 530,610 | $16.15 | $8.6M |
| Apr 10, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 828 | $15.75 | $13.0K |
| Apr 9, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 135,201 | $16.59 | $2.2M |
| Apr 8, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 353,242 | $16.32 | $5.8M |
| Apr 6, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 537,754 | $16.51 | $8.9M |
| Apr 2, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | SELL | 258,475 | $18.23 | $4.7M |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 2.8/10.
NEUTRAL
INST-CLUSTER
3/10
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanl
Jun 11, 2026
NEUTRAL
EFFECT
3/10
Vor Biopharma's S-3 registration statement (File No. 333-295346) became effective on May 6, 2026, en
May 7, 2026
NEUTRAL
S-3
3/10
Vor Biopharma filed an S-3 registration statement to register 5,338,078 shares of common stock for r
Apr 27, 2026
NEUTRAL
DEFA14A
2/10
Analysis based on filing metadata only — document content was unavailable. Vor Biopharma filed a DEF
Apr 27, 2026
BULLISH
7/10
Vor Biopharma announced that China's NMPA conditionally approved telitacicept for IgA nephropathy, t
Jun 8, 2026
NEUTRAL
5/10
Vor Biopharma announced a private placement of 5,338,078 shares at $14.05 per share, raising approxi
Mar 27, 2026
NEUTRAL
3/10
Vor Bio granted stock options and RSUs to 8 new employees as inducement awards under its 2023 Induce
Mar 23, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 5 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$37.88 mean target
+163.8% upside
Strong Buy (1.33)
$18.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $14.36 |
| Target Low | $18.00 |
| Target Mean | $37.88 |
| Target Median | $40.00 |
| Target High | $50.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.70 | $-0.82 | $-0.59 | 99.7% | +12.6% | 1↑ 2↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.77 | $-0.95 | $-0.59 | 99.4% | +10.1% | 1↑ 2↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-6.90 | $-8.00 | $-5.80 | 90.2% | -103.7% | 0↑ 3↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-3.74 | $-4.50 | $-2.58 | 45.8% | -1.0% | 2↑ 1↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.703 | |
| 7d ago | $-0.835 | +0.132 |
| 30d ago | $-0.805 | +0.102 |
| 60d ago | $-1.138 | +0.435 |
| 90d ago | $-1.138 | +0.435 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 14, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Apr 15, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 31, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Mar 30, 2026 | Jefferies | INITIATE | — | Buy |
| Mar 19, 2026 | Wells Fargo | INITIATE | — | Overweight |
| Jan 9, 2026 | Citigroup | INITIATE | — | Buy |
| Dec 19, 2025 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Dec 17, 2025 | TD Cowen | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Jan 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
other
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
<p align="center"><em>First regulatory approval for Sjögren’s disease (SjD)</em></p>
Jun 8, 2026
fda
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
<p align="center"><em>First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) </em></p>
Jun 1, 2026
other
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the t
May 28, 2026
other
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
<p align="justify">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment
May 13, 2026
earnings
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results
May 13, 2026
earnings_calendar
VOR Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings_calendar
VOR Q1 2026 Earnings Scheduled — 2026-05-12
May 4, 2026
other
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment
Apr 7, 2026
short_volume
Short Volume: VOR — 56.9% short (0.5M / 0.8M)
Short: 466,878 | Exempt: 12,704 | TRF Vol: 821,227 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
other
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatme
Mar 30, 2026
earnings
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
<p align="center"><em>First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease</em></p
Mar 30, 2026
fda
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
First and only dual BAFF/APRIL inhibitor in primary Sjögren’s disease, one of the largest autoimmune diseases without an approved therapy <pre>First a
Mar 27, 2026
offering
Vor Bio Announces $75 Million Private Placement with TCGX
<p align="justify">BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatme
Mar 27, 2026
short_volume
Short Volume: VOR — 70.2% short (0.4M / 0.5M)
Short: 383,782 | Exempt: 505 | TRF Vol: 546,437 | Short Ratio: 70.2% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
activist
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatme